Incheon: Samsung E and A Co. announced on Monday that it has successfully obtained a contract valued at 518.6 billion won (US$354.2 million) to construct a biopharmaceutical raw material production and research facility for Sartorius AG in Songdo, west of Seoul.
According to Yonhap News Agency, the plant will be built for Sartorius Korea, the South Korean branch of the German life sciences firm, within the Songdo Free Economic Zone in Incheon. The facility is set to produce single-use bioprocessing bags and pharmaceutical membrane filters. Additionally, it will offer clinical contract research organization (CRO) services once operational.
Samsung E and A will independently manage the engineering, procurement, and construction phases of the project, with an anticipated completion date in 2027.